| Missed Opportunities on Emergency Remdesivir Use #MMPMID32579163Sarpatwari A; Kaltenboeck A; Kesselheim ASJAMA 2020[Jul]; 324 (4): 331-332 PMID32579163show ga
ä|*Betacoronavirus[MESH]|Adenosine Monophosphate/adverse effects/*analogs & derivatives/economics/supply & distribution/therapeutic use[MESH]|Alanine/adverse effects/*analogs & derivatives/economics/supply & distribution/therapeutic use[MESH]|Antiviral Agents/adverse effects/economics/supply & distribution/*therapeutic use[MESH]|COVID-19[MESH]|COVID-19 Drug Treatment[MESH]|Clinical Trials, Phase III as Topic[MESH]|Coronavirus Infections/*drug therapy/epidemiology[MESH]|Drug Approval[MESH]|Drug Costs[MESH]|Drugs, Investigational/adverse effects/economics/supply & distribution/*therapeutic use[MESH]|Hemorrhagic Fever, Ebola/drug therapy[MESH]|Humans[MESH]|Length of Stay[MESH]|National Institute of Allergy and Infectious Diseases (U.S.)[MESH]|Pandemics[MESH]|Pneumonia, Viral/*drug therapy/epidemiology[MESH]|Registries[MESH]|SARS-CoV-2[MESH]|Treatment Outcome[MESH]
DeepDyve Pubget Overpricing |
|